| 4-D | Die Deutsche Diabetes Dialyse Studie |
| 4S | Scandinavian Simvastatin Survival Study |
| ACCORD | Action to Control Cardiovascular Risk in Diabetes |
| ACVD | Atherosclerotic Cardiovascular Disease |
| AFCAPS/TexCAPS | Air Force/Texas Coronary Atherosclerosis Prevention Study |
| AHA | American Heart Association |
| AJKD | American Journal of Kidney Diseases |
| ALERT | Assessment of Lescol in Renal Transplantation |
| ALLHAT | Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial |
| ALLIANCE | Aggressive Lipid Lowering Initiation Abates New Cardiac Events |
| ASPEN | Atorvastatin as Prevention of Coronary Heart Disease Endpoints in Patients with Non-Insulin-Dependent Diabetes Mellitus |
| AST | American Society of Transplantation |
| ATP III | Adult Treatment Panel III |
| AUC | Area under the (concentration-time) curve |
| AZA | Azathioprine |
| BIP | Bezafibrate Infarction Prevention |
| CARDS | Collaborative Atorvastatin Diabetes Study |
| CARE | Cholesterol and Recurrent Events |
| CHD | Coronary Heart Disease |
| CHOL | Cholesterol |
| CK | Creatinine phosphokinase |
| CKD | Chronic kidney disease |
| CMV | Cytomegalovirus |
| Cr | Creatinine (serum) |
| CsA | CyclosporineA |
| CVD | Cardiovascular disease |
| DOQI | Dialysis Outcomes Quality Initiative |
| EDTA | European Dialysis and Transplantation Association |
| EPA | Eicosapentaenoic acid (20:n-3) |
| ESRD | End-stage renal disease |
| EXCEL | Expanded Clinical Evaluation of Lovastatin |
| FIELD | Fenofibrate Intervention and Event Lowering in Diabetes |
| FMC | Fresenius Medical Care |
| GFR | Glomerular filtration rate |
| HD | Heart disease |
| HDL | High-density lipoprotein |
| HPS | The Heart Protection Study |
| IDEAL | Incremental Decrease in Endpoints Through Aggressive Lipid Lowering |
| IDL | Intermediate-density lipoproteins |
| KDOQI | Kidney Disease Outcomes Quality Initiative |
| LDL | Low-density lipoprotein |
| LIPID | Long-Term Intervention with Pravastatin in Ischaemic Disease |
| LMWH | Low molecular weight heparin |
| Lp(a) | Lipoprotein (a) |
| MI | Myocardial infarction |
| MIRACL | Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering |
| MMF | Mycophenolate mofetil |
| MRC | Medical Research Council |
| N | Number (of data points) |
| NCEP | National Cholesterol Education Program |
| NCEP-C | National Cholesterol Education Program-Children |
| NHANES | National Health and Nutrition Examination Survey |
| NHLBI | National Heart, Lung and Blood Institute |
| NIH | National Institutes of Health |
| NKF | National Kidney Foundation |
| NKF-KDOQI | National Kidney Foundation Kidney Disease Outcomes Quality Initiative |
| NS | Nephrotic syndrome |
| PDAY | Pathobiological Determinants of Atherosclerosis in Youth |
| PREVEND IT | Prevention of REnal and Vascular ENdstage Disease Intervention Trial |
| PRINCE | Pravastatin Inflammation/C-Reactive Protein Evaluation |
| PROSPER | Prospective Study of Pravastatin in the Elderly at Risk |
| PROVE IT | Pravastatin or Atorvastatin in Evaluation and Infection Therapy |
| SEARCH | Study Evaluating Additional Reductions in Cholesterol and Homocysteine |
| SHARP | The Study of Heart and Renal Protection |
| SPARCL | Stroke Prevention by Aggressive Reduction in Cholesterol Levels |
| TG, TRIG | Triglycerides |
| TLC | Therapeutic lifestyle changes |
| TNT | Treating to New Targets |
| USFDA | United States Food and Drug Administration |
| VA-HIT | Veterans Administration High-Density Lipoprotein Cholesterol Intervention Trial |
| VLDL | Very low-density lipoprotein |
| WOSCOPS | West of Scotland Coronary Prevention Study |